Interim report January – September 2022
The period in summary
Third quarter July 1 – September 30, 2022
– On July 20th, 2022 Intervacc announced that the company had received an order for the equivalent of approximately SEK 3 million from Dechra Pharmaceuticals PLC. The order concerns delivery of Strangvac vials to be used for launch in selected European countries.
– On August 17 we announced that Strangvac began being sold in the UK, which is expected to be a significant country for the vaccine.
– CEO Andreas Andersson and three other key persons have subscribed for 330,455 shares in Intervacc by